文献
J-GLOBAL ID:201802217297227220
整理番号:18A0017807
または不耐性難治性進行性胃癌あるいは胃食道接合部癌患者におけるニボルマブ,少なくとも2以前の化学療法レジメン(ONO 4538 12, ATTRACTION 2):無作為化二重盲検プラセボ対照第3相試験【Powered by NICT】
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
著者 (25件):
Kang Yoon-Koo
(Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea)
,
Boku Narikazu
(Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)
,
Satoh Taroh
(Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan)
,
Ryu Min-Hee
(Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea)
,
Chao Yee
(Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan)
,
Kato Ken
(Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)
,
Chung Hyun Cheol
(Division of Medical Oncology, Medical Oncology Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea)
,
Chen Jen-Shi
(Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan)
,
Muro Kei
(Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan)
,
Kang Won Ki
(Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea)
,
Yeh Kun-Huei
(Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan)
,
Yoshikawa Takaki
(Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan)
,
Oh Sang Cheul
(Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea)
,
Bai Li-Yuan
(Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan)
,
Tamura Takao
(Department of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan)
,
Lee Keun-Wook
(Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea)
,
Hamamoto Yasuo
(Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan)
,
Kim Jong Gwang
(Kyungpook National University School of Medicine, Daegu, South Korea)
,
Chin Keisho
(Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan)
,
Oh Do-Youn
(Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea)
,
Minashi Keiko
(Department of Clinical Trial Promotion, Chiba Cancer Center, Chiba, Japan)
,
Cho Jae Yong
(Department of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea)
,
Tsuda Masahiro
(Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan)
,
Chen Li-Tzong
(National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan)
,
Chen Li-Tzong
(National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan)
資料名:
Lancet
(Lancet)
巻:
390
号:
10111
ページ:
2461-2471
発行年:
2017年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)